These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 28102546)

  • 1. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Higgins C; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
    Aslam AA; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
    Kerem E; Konstan MW; De Boeck K; Accurso FJ; Sermet-Gaudelus I; Wilschanski M; Elborn JS; Melotti P; Bronsveld I; Fajac I; Malfroot A; Rosenbluth DB; Walker PA; McColley SA; Knoop C; Quattrucci S; Rietschel E; Zeitlin PL; Barth J; Elfring GL; Welch EM; Branstrom A; Spiegel RJ; Peltz SW; Ajayi T; Rowe SM;
    Lancet Respir Med; 2014 Jul; 2(7):539-47. PubMed ID: 24836205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
    Smith S; Rowbotham NJ
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD001021. PubMed ID: 36373968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
    Southern KW; Solis-Moya A; Kurz D; Smith S
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulised hypertonic saline for cystic fibrosis.
    Wark P; McDonald VM
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis.
    Dawson S; Girling CJ; Cowap L; Clark-Carter D
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD013766. PubMed ID: 36989170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise versus airway clearance techniques for people with cystic fibrosis.
    Heinz KD; Walsh A; Southern KW; Johnstone Z; Regan KH
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013285. PubMed ID: 35731672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Smith S; Rowbotham NJ; Charbek E
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008319. PubMed ID: 35914011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulised hypertonic saline for cystic fibrosis.
    Wark P; McDonald VM; Smith S
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD001506. PubMed ID: 37319354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting inhaled bronchodilators for cystic fibrosis.
    Smith S; Edwards CT
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD012102. PubMed ID: 29253920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Smith S; Rowbotham NJ; Charbek E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008319. PubMed ID: 30376155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.